March 27, 2017 / 12:10 PM / 8 months ago

BRIEF-Strongbridge Biopharma Plc phase 3 sonics study more than 80 pct enrolled

March 27 (Reuters) - Strongbridge Biopharma Plc

* Strongbridge Biopharma Plc provides corporate update and reports full-year 2016 financial results

* Strongbridge Biopharma Plc - phase 3 sonics study is now more than 80 percent enrolled and we remain on track to fully enroll study during Q2

* Strongbridge Biopharma Plc - on schedule to commence enrollment in logics, supportive phase 3 study for COR-003, in middle of this year

* Strongbridge Biopharma Plc - COR-003 phase 3 clinical development program remains on track Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below